Elemento

新型コロナ治療に光 ウイルス侵入防ぐ物質を開発(2020年11月19日) - Developed a substance to prevent invasion of light virus for new corona treatment (November 19, 2020)

Título (Dublin Core)

新型コロナ治療に光 ウイルス侵入防ぐ物質を開発(2020年11月19日) - Developed a substance to prevent invasion of light virus for new corona treatment (November 19, 2020)

Description (Dublin Core)

新型コロナウイルスの有力な治療薬になる可能性があります。京都府立医科大学などの研究チームは新型コロナウイルスが細胞に侵入するのを防ぐ特殊なたんぱく質を開発したと発表しました。  京都府立医科大学・星野温助教:「(新型コロナウイルス)治療薬がまだ『これ』というのが確立されてませんので、その一つの大きな候補となる開発技術になりますので、大きく社会に貢献できるものと期待します」  新型コロナウイルスは表面にあるトゲが人の細胞の表面にある「ACE2」と呼ばれる突起と結合することで細胞内に侵入します。京都府立医科大学の星野温助教らの研究チームは細胞の突起に結合する前に、ウイルス表面のトゲと結合する特殊なたんぱく質を開発しました。トゲと結合する力がACE2よりも100倍以上強いということです。このたんぱく質を軽症や中等症の患者に投与することで感染した後に症状の悪化を抑える効果が期待できるということです。また、似たような仕組みの抗体製剤と比べてウイルスが変異しても効果が変わらないとしています。  京都府立医科大学・星野温助教:「抗体製剤は比較的スパイク(ウイルスのトゲ)と点でくっついている感じですね。私たちのたんぱく質製剤は元々、スパイクがACE2(細胞の突起)にくっつく面をすべてカバーしているので」  今後は企業と協力して来年度に臨床試験を始め、再来年度の実用化を目指したいとしています。

It has the potential to be a powerful remedy for the new coronavirus. Research teams including Kyoto Prefectural University of Medicine have announced that they have developed a special protein that prevents the new coronavirus from invading cells.

Assistant Professor Atsushi Hoshino, Kyoto Prefectural University of Medicine: "(New coronavirus) Therapeutic drug has not yet been established, so it will be one of the major candidates for development technology, and will greatly contribute to society. I expect it to be possible. "
The new coronavirus invades the cells by binding the spikes on the surface to the protrusions called "ACE2" on the surface of human cells. A research team led by Assistant Professor Atsushi Hoshino of Kyoto Prefectural University of Medicine has developed a special protein that binds to spikes on the surface of the virus before it binds to the protrusions of cells. It means that the force to bind to spikes is more than 100 times stronger than ACE2. By administering this protein to patients with mild or moderate illness, it can be expected to have the effect of suppressing the worsening of symptoms after infection. In addition, compared to antibody preparations with a similar mechanism, the effect does not change even if the virus mutates.
Atsushi Hoshino, Assistant Professor, Kyoto Prefectural University of Medicine: "It feels like antibody preparations are relatively sticking to spikes (virus spikes). Our protein preparations already have spikes sticking to ACE2 (cell protrusions) and it covers all of them. "
In the future, we would like to cooperate with companies to start clinical trials next year and aim for practical application in the following year of next year.

Video translated by Youngbin Noh

Date (Dublin Core)

November 19, 2020

Creator (Dublin Core)

ANNnewsCH

Contributor (Dublin Core)

Youngbin Noh

Event Identifier (Dublin Core)

HSE

Partner (Dublin Core)

Arizona State University

Tipo (Dublin Core)

Screenshot, video

Link (Bibliographic Ontology)

Controlled Vocabulary (Dublin Core)

English Health & Wellness
English Science
English News coverage

Curator's Tags (Omeka Classic)

Kyoto Prefectural University of Medicine
protein
ACE2
suppress
clinical trial
Japan

Contributor's Tags (a true folksonomy) (Friend of a Friend)

virus
spike protein
Japan

Linked Data (Dublin Core)

Date Submitted (Dublin Core)

11/19/2020

Date Modified (Dublin Core)

11/19/2020
03/18/2021

Date Created (Dublin Core)

11/19/2020

Colecciones

This item was submitted on November 19, 2020 by Youngbin Noh using the form “Share Your Story” on the site “A Journal of the Plague Year”: https://covid-19archive.org/s/archive

Click here to view the collected data.

New Tags

I recognize that my tagging suggestions may be rejected by site curators. I agree with terms of use and I accept to free my contribution under the licence CC BY-SA